Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Medical Oncology Department, MD Anderson Cancer Center, Madrid, C/ Arturo Soria, 270, 28033 - Madrid. Spain. agonzalezm@seom.org.
Antonio
A
González-Martín
Emilio
E
Alba
Eva
E
Ciruelos
Javier
J
Cortés
Antonio
A
Llombart
Ana
A
Lluch
Raquel
R
Andrés
Isabel
I
Álvarez
José Manuel
JM
Aramendía
Francisco Ayala
FA
de la Peña
Agustí
A
Barnadas
Norberto
N
Batista
Lourdes
L
Calvo
Elena
E
Galve
Andrés
A
García-Palomo
José Ángel
JÁ
García-Sáenz
Juan
J
de la Haba
Rafael
R
López
Guillermo
G
López-Vivanco
Noelia
N
Martínez-Jáñez
Eduardo Martínez
EM
de Dueñas
Arrate
A
Plazaola
Álvaro
Á
Rodríguez-Lescure
Manuel
M
Ruiz
Pedro
P
Sánchez-Rovira
Ana
A
Santaballa
Miguel Ángel
MÁ
Seguí
Ignasi
I
Tusquets
Pilar
P
Zamora
Miguel
M
Martín
D000418:Albumins / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D053758:Nanoparticles / Q000008:administration & dosage*; D017239:Paclitaxel / Q000494:pharmacology* / Q000627:therapeutic use*; D043823:Taxoids / Q000494:pharmacology / Q000627:therapeutic use
C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D001952:Bridged-Ring Compounds; D043823:Taxoids; C080625:taxane; D017239:Paclitaxel